Skip to main content

Advertisement

SpringerLink
Log in

Duchenne Muscular Dystrophy: the Heart of the Matter

  • Clinical Heart Failure (T Meyer, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Duchenne muscular dystrophy is one of many neuromuscular disorders, but it frequently causes severe disability early in life and early death. Cardiac involvement is an important cause of morbidity and mortality.

Recent Findings

Heart disease in Duchenne muscular dystrophy can include a cardiomyopathy leading to end-stage heart failure along with associated supraventricular and ventricular arrhythmias.

Summary

This article reviews the diagnosis and treatment of heart disease in Duchenne muscular dystrophy as well as emerging therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. GBA D. Recherches sur la paralysie musculaire pseudo-hypertrophique ou paralysie myo-sclerosique. Arch Gen Med. 1868;11:5–25.

    Google Scholar 

  2. Van Ruiten HJA, Marini Bettolo C, Cheetham T, Eagle M, Lochmuller H, Strauber V, et al. Why are some patients with Duchenne muscular dystrophy dying young? An analysis of causes of death in North East England. Eur J Paediatr Neurol. 2016;20:904–9.

    Article  CAS  PubMed  Google Scholar 

  3. EM MN. New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu Rev Med. 2007;58:75–88.

    Article  CAS  Google Scholar 

  4. Eagle M, Baudoin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926–9.

    Article  PubMed  Google Scholar 

  5. . Binkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:251–67 Outlines critical diagnostic and management practice.

    Article  Google Scholar 

  6. Mah JK, Korngut L, Fiest KM, Dykeman J, Day LJ, Pringsheim T, et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43(1):163–77.

    Article  PubMed  Google Scholar 

  7. Buddhe S, Cripe L, Friedland-Little J, Kertesz N, Eghtesady P, Finder J, et al. Cardiac management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(Supplement 2):S72–81.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Neri M, Valli E, Alfano G, et al. The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5′ X-linked dilated cardiomyopathy. BMC Med Genet. 2012;13:20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yamamoto T, Awano H, Zhang Z, Sakuma M, Kitaaki S, Matsumoto M, et al. Cardiac dysfunction in Duchenne muscular dystrophy is less frequent in patients with mutations in the dystrophin Dp116 coding region than in other regions. Circ Genom Precis Med. 2018;11:e001782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kamdar F, Garry D. Dystrophin-deficient cardiomyopathy. JACC. 2016;67(21):2533–46.

    Article  CAS  PubMed  Google Scholar 

  11. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990;345(6273):315–9.

    Article  CAS  PubMed  Google Scholar 

  12. Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20:18168–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Whitehead NP, Yeung EW, Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol. 2006;33:657–62.

    Article  CAS  PubMed  Google Scholar 

  14. Turner PR, Westwood T, Regen CM, Steinhardt RA. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature. 1988;335(6192):735–8.

    Article  CAS  PubMed  Google Scholar 

  15. Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31:121–5.

    PubMed  PubMed Central  Google Scholar 

  16. Takami Y, Takeshima Y, Awano H, Okizuka Y, Yagi M, Matsuo M. High incidence of electrocardiogram abnormalities in young patients with Duchenne muscular dystrophy. Pediatr Neurol. 2008;39(6):399–403.

    Article  PubMed  Google Scholar 

  17. Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. 2012;9:1890–5.

    Article  PubMed  Google Scholar 

  18. Sanyal SK, Johnson WW, Dische MR, Pitner SE, Beard C. Dystrophic degeneration of papillary muscle and ventricular myocardium. A basis for mitral valve prolapse in Duchenne’s muscular dystrophy. Circulation. 1980;62(2):430.

    Article  CAS  PubMed  Google Scholar 

  19. Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2008;155:998–1005.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990;26:271–7.

    Article  CAS  PubMed  Google Scholar 

  21. Florian A, Rosch S, Bietenbeck M, et al. Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2016;17:326–33.

    Article  PubMed  Google Scholar 

  22. . Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, Judge DP, Lal AK, Markham LW, Parks WJ, Tsuda T, Wang PJ, Yoo S. Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association. Circulation. 2017;136:00–00. Guidelines on management of DMD.

  23. Hor KN, Johnston P, Kinnett K, Mah ML, Stiver C, Markham L, et al. Progression of Duchenne cardiomyopathy presenting with chest pain and troponin elevation. J Neuromuscul Dis. 2017;4(4):307–14.

    Article  PubMed  Google Scholar 

  24. Nishizawa T, Yasuma f, Sakai M, Kuru S, Kimura S, Shibata R, et al. Abstract 2498: Minor myocardial damage and LV dysfunction in patients with Duchenne muscular dystrophy-the preventive efficacy of carvedilol on plasma cardiac troponin I. Circulation. 2007;116:II_551.

    Google Scholar 

  25. Johnston P, Hor K, Cripe L, Stiver C. Duchenne muscular dystrophy patients with chest pain require cardiac evaluation: a report of eight DMD patients presenting with chest pain, marked troponin elevation, and worsening cardiomyopathy. Neuromuscul Disord. 2017;27(2):S113.

    Google Scholar 

  26. Voleti S, Olivieri L, Hamann K, Gordish-Dressman H, Spurney C. Abstract 16715: troponin I levels correlate with cardiac magnetic resonance late gadolinium enhancement and native T1 values in Duchenne muscular dystrophy cardiomyopathy and identify early disease progression. Circulation. 2018;138:A16715.

    Google Scholar 

  27. Rapezzi C, Leone O, Biagini E, Coccolo F. Echocardiographic clues to diagnosis of dystrophin related dilated cardiomyopathy. Heart. 2007;93:10.

  28. Poonja S, JK PAMN, Fine NM, Greenway SC. Current cardiac imaging approaches in Duchenne muscular dystrophy. J Clin Neuromusc Dis. 2018;20(2):85–93.

    Article  Google Scholar 

  29. Silva MC, Meira ZM, Gurgel Giannetti J, da Silva MM, Campos AF, Barbosa Mde M, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol. 2007;49:1874–9.

    Article  PubMed  Google Scholar 

  30. Puchalski MD, Williams RV, Askovich B, Sower CT, Hor KH, Su JT, et al. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? Int J Cardiovasc Imaging. 2009;25:57–63.

    Article  PubMed  Google Scholar 

  31. Hagenbuch SC, Gottliebson WM, Wansapura J, Mazur W, Fleck R, Benson DW, et al. Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. Am J Cardiol. 2010;105:1451–5.

    Article  PubMed  Google Scholar 

  32. Menon SC, Etheridge SP, Liesemer KN, Williams RV, Bardsley T, Heywood MC, et al. Predictive value of myocardial delayed enhancement in Duchenne muscular dystrophy. Pediatr Cardiol. 2014;35:1279–85.

    Article  PubMed  Google Scholar 

  33. Tandon A, Villa CR, Hor KN, Jefferies JL, Gao Z, Towbin JA, et al. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy. J Am Heart Assoc. 2015;26:4(4).

    Google Scholar 

  34. Mavrogeni S, Papavasiliou A, Douskou M, Kolovou G, Papadopoulou E, Cokkinos DV. Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study. Eur J Paediatr Neurol. 2009;13(1):34–40.

    Article  PubMed  Google Scholar 

  35. Yancy C, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin M, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.

    Article  PubMed  Google Scholar 

  36. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45:855–7.

    Article  CAS  PubMed  Google Scholar 

  37. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J. 2007;154:596–602.

    Article  CAS  PubMed  Google Scholar 

  38. Kajimoto H, Ishigaki K, Okumura K, Tomimatsu H, Nakazawa M, Saito K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J. 2006;70:991–4.

    Article  CAS  PubMed  Google Scholar 

  39. Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern Med. 2010;49:1357–63.

    Article  CAS  PubMed  Google Scholar 

  40. Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol. 2012;110:98–102.

    Article  CAS  PubMed  Google Scholar 

  41. Kwon HW, Kwon BS, Kim GB, Chae JH, Park JD, Bae EJ, et al. The effect of enalapril and carvedilol on left ventricular dysfunction in middle childhood and adolescent patients with muscular dystrophy. Korean Circ J. 2012;42:184–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of betablockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol. 2009;53(1):72–8.

    Article  PubMed  Google Scholar 

  43. Dittrick S, Graf E, Trollmann R, Neudorf U, Schara U, Heilmannn A, et al. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. Orphanet J Rare Dis. 2019;14:105.

    Article  Google Scholar 

  44. Raman SV, Hor KN, Mazur W, Halnon NJ, Kissel JT, He X, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14:153–61.

  45. De Benedittis G, Rosa GD, D’Ettorre E, Piscitelli P, Distante A, de Gregorio C. Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: a chance for slowing progression of heart failure? Int J Cardiol. 2016;223:286–8.

    Article  PubMed  Google Scholar 

  46. Finsterer J, Stollberger C, Berger E. Beneficial effect of ivabradine in dilated cardiomyopathy from Becker muscular dystrophy. Herz. 2012;37(6):702–5.

    Article  CAS  PubMed  Google Scholar 

  47. Fayssoil A, Nardi O, Annane D, Orlikowski D. Successful cardiac resynchronization therapy in Duchenne muscular dystrophy: a 5-year followup. Presse Med. 2014;43:330–1.

    Article  PubMed  Google Scholar 

  48. 330. Kono T, Ogimoto A, Nishimura K, Yorozuya T, Okura T, Higaki J. Cardiac resynchronization therapy in a young patient with Duchenne muscular dystrophy. Int Med Case Rep J 2015;8:173–175.

  49. Wu RS, Gupta S, Brown RN, Yancy CW, Wald JW, Kaiser P, et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients. J Heart Lung Transplant. 2010;29:432–8.

    Article  PubMed  Google Scholar 

  50. Rees W, Schüler S, Hummel M, Hetzer R. Heart transplantation in patients with muscular dystrophy associated with end-stage cardiomyopathy. J Heart Lung Transplant. 1993;12:804–7.

    CAS  PubMed  Google Scholar 

  51. Amodeo A, Adorisio R. Left ventricular assist device in Duchenne cardiomyopathy: can we change the natural history of cardiac disease? Int J Cardiol. 2012;161:e43.

    Article  PubMed  Google Scholar 

  52. Ryan TD, Jefferies JL, Sawnani H, Wong BL, Gardner A, Del Corral M, et al. Implantation of the HeartMate II and HeartWare left ventricular assist devices in patients with Duchenne muscular dystrophy: lessons learned from the first applications. ASAIO J. 2014;60:246–8.

    Article  PubMed  Google Scholar 

  53. Iodice F, Testa G, Averardi M, Brancaccio G, Amodeo A, Cogo P. Implantation of a left ventricular assist device as a destination therapy in Duchenne muscular dystrophy patients with end stage cardiac failure: management and lessons learned. Neuromuscul Disord. 2015;25(1):19–23.

    Article  PubMed  Google Scholar 

  54. Perri G, Filippelli S, Adorisio R, Iacobelli R, Iodice F, Testa G, et al. Left ventricular assist device as destination therapy in cardiac endstage dystrophinopathies: midterm results. J Thorac Cardiovasc Surg. 2017;153(3):669–74.

    Article  PubMed  Google Scholar 

  55. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637–47.

    Article  CAS  PubMed  Google Scholar 

  56. Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79(2):257–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Li J, et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci. 2008;105(39):14814–9.

    Article  CAS  PubMed  Google Scholar 

  58. Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477.

    Article  CAS  PubMed  Google Scholar 

  59. McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489.

    Article  CAS  PubMed  Google Scholar 

  60. Taylor M, Jefferies J, Byrne B, Lima J, Ambale-Venkatesh B, Ostovaneh MR, et al. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology. 2019;92(8):e866–78.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve. 2013;47(5):649–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Bengtsson NE, Seto JT, Hall JK, Chamberlain JS, Odom GL. Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet. 2016;25(R1):R9–R17.

    Article  CAS  PubMed  Google Scholar 

  63. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med. 2010;363:1429–37.

  64. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012;20:443–55.

    Article  CAS  PubMed  Google Scholar 

  65. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science. 2014;345:1184–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351:400–3.

    Article  CAS  PubMed  Google Scholar 

  67. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351:403–7.

    Article  CAS  PubMed  Google Scholar 

  68. Amoasii L, JCW H, Li H, Sanchez-Ortiz E, Mireault A, Caballero D, et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science. 2018;362(6410):86–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Massachusetts, 55 Lake Avenue North, Worcester, MA, 01532, USA

    Jeffrey A. Shih, Alejandro Folch & Brenda L. Wong

Authors
  1. Jeffrey A. Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alejandro Folch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brenda L. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey A. Shih.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Clinical Heart Failure.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shih, J.A., Folch, A. & Wong, B.L. Duchenne Muscular Dystrophy: the Heart of the Matter. Curr Heart Fail Rep 17, 57–66 (2020). https://doi.org/10.1007/s11897-020-00456-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-020-00456-0

Keywords

Search

Navigation